Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet as second-line therapy for relapsed epithelial ovarian carcinoma
2010-023755-28Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Dec 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin and carboplatin in epithelial ovarian cancer (EOC) (2 cohorts), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Complete response. Started Dec 2010; status: active.
02
Drugs
doxorubicincarboplatin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2010-023755-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023755-28.